TY - JOUR AU - Lim, Y. C. AU - Desta, Z. AU - Flockhart, D. A. AU - Skaar, T. C. PY - 2005 DA - 2005// TI - Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen JO - Cancer Chemother Pharmacol VL - 55 UR - https://doi.org/10.1007/s00280-004-0926-7 DO - 10.1007/s00280-004-0926-7 ID - Lim2005 ER - TY - JOUR AU - Johnson, M. D. AU - Zuo, H. AU - Lee, K. H. AU - Trebley, J. P. AU - Rae, J. M. AU - Weatherman, R. V. PY - 2004 DA - 2004// TI - Pharmacological characterizatioan of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen JO - Breast Cancer Res Treat VL - 85 UR - https://doi.org/10.1023/B:BREA.0000025406.31193.e8 DO - 10.1023/B:BREA.0000025406.31193.e8 ID - Johnson2004 ER - TY - JOUR AU - Wu, X. AU - Hawse, J. R. AU - Subramaniam, M. AU - Goetz, M. P. AU - Ingle, J. N. AU - Spelsberg, T. C. PY - 2009 DA - 2009// TI - The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor α for degradation in breast cancer cells JO - Cancer Res VL - 69 UR - https://doi.org/10.1158/0008-5472.CAN-08-3933 DO - 10.1158/0008-5472.CAN-08-3933 ID - Wu2009 ER - TY - JOUR AU - Stearns, V. AU - Johnson, M. D. AU - Rae, J. M. AU - Morocho, A. AU - Novielli, A. AU - Bhargava, P. PY - 2003 DA - 2003// TI - Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine JO - J Natl Cancer Inst VL - 95 UR - https://doi.org/10.1093/jnci/djg108 DO - 10.1093/jnci/djg108 ID - Stearns2003 ER - TY - JOUR AU - Borges, S. AU - Desta, Z. AU - Li, L. AU - Skaar, T. C. AU - Ward, B. A. AU - Nguyen, A. PY - 2006 DA - 2006// TI - Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment JO - Clin Pharmacol Ther VL - 80 UR - https://doi.org/10.1016/j.clpt.2006.03.013 DO - 10.1016/j.clpt.2006.03.013 ID - Borges2006 ER - TY - JOUR AU - Jin, Y. AU - Desta, Z. AU - Stearns, V. AU - Ward, B. AU - Ho, H. AU - Lee, K. H. PY - 2005 DA - 2005// TI - CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment JO - J Natl Cancer Inst VL - 97 UR - https://doi.org/10.1093/jnci/dji005 DO - 10.1093/jnci/dji005 ID - Jin2005 ER - TY - JOUR AU - Reid, J. M. AU - Goetz, M. P. AU - Buhrow, S. A. AU - Walden, C. AU - Safgren, S. L. AU - Kuffel, M. J. PY - 2014 DA - 2014// TI - Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies JO - Cancer Chemother Pharmacol VL - 74 UR - https://doi.org/10.1007/s00280-014-2605-7 DO - 10.1007/s00280-014-2605-7 ID - Reid2014 ER - TY - JOUR AU - Gong, I. Y. AU - Teft, W. A. AU - Ly, J. AU - Chen, Y. H. AU - Alicke, B. AU - Kim, R. B. PY - 2013 DA - 2013// TI - Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts JO - Breast Cancer Res Treat VL - 139 UR - https://doi.org/10.1007/s10549-013-2530-1 DO - 10.1007/s10549-013-2530-1 ID - Gong2013 ER - TY - JOUR AU - Goetz, M. P. AU - Suman, V. J. AU - Reid, J. M. AU - Northfelt, D. W. AU - Mahr, M. A. AU - Ralya, A. T. PY - 2017 DA - 2017// TI - First-in-human phase I study of the tamoxifen metabolite Z-endoxifen in women with endocrine-refractory metastatic breast cancer JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.73.3246 DO - 10.1200/JCO.2017.73.3246 ID - Goetz2017 ER - TY - JOUR AU - Long, B. J. AU - Jelovac, D. AU - Handratta, V. AU - Thiantanawat, A. AU - MacPherson, N. AU - Ragaz, J. PY - 2004 DA - 2004// TI - Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model JO - J Natl Cancer Inst VL - 96 UR - https://doi.org/10.1093/jnci/djh076 DO - 10.1093/jnci/djh076 ID - Long2004 ER - TY - JOUR AU - Macedo, L. F. AU - Sabnis, G. J. AU - Goloubeva, O. G. AU - Brodie, A. PY - 2008 DA - 2008// TI - Combination of anastrozole with fulvestrant in the intramural aromatase xenograft model JO - Cancer Res VL - 68 UR - https://doi.org/10.1158/0008-5472.CAN-07-6807 DO - 10.1158/0008-5472.CAN-07-6807 ID - Macedo2008 ER - TY - JOUR AU - Yue, W. AU - Zhou, D. AU - Chen, S. AU - Brodie, A. PY - 1994 DA - 1994// TI - A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene JO - Cancer Res VL - 54 ID - Yue1994 ER - TY - JOUR AU - Peterson, E. A. AU - Jenkins, E. C. AU - Lofgren, K. A. AU - Chandiramani, N. AU - Liu, H. AU - Aranda, E. PY - 2015 DA - 2015// TI - Amphiregulin is a critical downstream effector of estrogen signaling in ERα-positive breast cancer JO - Cancer Res VL - 75 UR - https://doi.org/10.1158/0008-5472.CAN-15-0709 DO - 10.1158/0008-5472.CAN-15-0709 ID - Peterson2015 ER - TY - JOUR AU - Kuske, B. AU - Naughton, C. AU - Moore, K. AU - Macleod, K. G. AU - Miller, W. R. AU - Clarke, R. PY - 2006 DA - 2006// TI - Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models JO - Endocr Relat Cancer VL - 13 UR - https://doi.org/10.1677/erc.1.01257 DO - 10.1677/erc.1.01257 ID - Kuske2006 ER - TY - JOUR AU - Sun, J. M. AU - Spencer, V. A. AU - Li, L. AU - Yu Chen, H. AU - Yu, J. AU - Davie, J. R. PY - 2005 DA - 2005// TI - Estrogen regulation of trefoil factor 1 expression by estrogen receptor alpha and Sp proteins JO - Exp Cell Res VL - 302 UR - https://doi.org/10.1016/j.yexcr.2004.08.015 DO - 10.1016/j.yexcr.2004.08.015 ID - Sun2005 ER - TY - JOUR AU - Subramanian, A. AU - Tamayo, P. AU - Mootha, V. K. AU - Mukherjee, S. AU - Ebert, B. L. AU - Gillette, M. A. PY - 2005 DA - 2005// TI - Gene set enrichment analysis: a knowledge-based approach for interpreting genomw-wide expression profiles JO - Proc Natl Acad Sci U S A VL - 102 UR - https://doi.org/10.1073/pnas.0506580102 DO - 10.1073/pnas.0506580102 ID - Subramanian2005 ER - TY - JOUR AU - Hänzelmann, S. AU - Castelo, R. AU - Guinney, J. PY - 2013 DA - 2013// TI - GSVA: gene set variation analysis for microarray and RNA-seq data JO - BMC Bioinformatics VL - 14 UR - https://doi.org/10.1186/1471-2105-14-7 DO - 10.1186/1471-2105-14-7 ID - Hänzelmann2013 ER - TY - JOUR AU - Gingery, A. AU - Subramaniam, M. AU - Pitel, K. S. AU - Reese, J. M. AU - Cicek, M. AU - Lindenmaier, L. B. PY - 2014 DA - 2014// TI - The effects of a novel hormonal breast cancer therapy, endoxifen, on the mouse skeleton JO - PLoS One VL - 9 UR - https://doi.org/10.1371/journal.pone.0098219 DO - 10.1371/journal.pone.0098219 ID - Gingery2014 ER - TY - JOUR AU - Manavathi, B. AU - Dey, O. AU - Gajulapalli, V. N. AU - Bhatia, R. S. AU - Bugide, S. AU - Kumar, R. PY - 2013 DA - 2013// TI - Derailed estrogen signaling and breast cancer: an authentic couple JO - Endocr Rev VL - 34 UR - https://doi.org/10.1210/er.2011-1057 DO - 10.1210/er.2011-1057 ID - Manavathi2013 ER - TY - JOUR AU - Guerrero-Zotano, A. AU - Mayer, I. A. AU - Arteaga, C. L. PY - 2016 DA - 2016// TI - PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment JO - Cancer Metastasis Rev VL - 35 UR - https://doi.org/10.1007/s10555-016-9637-x DO - 10.1007/s10555-016-9637-x ID - Guerrero-Zotano2016 ER - TY - JOUR AU - Avan, A. AU - Narayan, R. AU - Giovannetti, E. AU - Peters, G. J. PY - 2016 DA - 2016// TI - Role of Akt signaling in resistance to DNA-targeted therapy JO - World J Clin Oncol VL - 7 UR - https://doi.org/10.5306/wjco.v7.i5.352 DO - 10.5306/wjco.v7.i5.352 ID - Avan2016 ER -